FDA Approves Amgen’s Lung Cancer Treatment #

The Food and Drug Administration has given the green light to Amgen’s Imdelltra as a second or later-line treatment option for patients with advanced small-cell lung cancer. This deadly form of lung cancer affects around 15% of cases and has a poor prognosis, with a five-year survival rate of only 3%. In clinical trials, Imdelltra has demonstrated efficacy in reducing tumor growth and extending the lives of patients with small-cell lung cancer. The approval of Imdelltra provides new hope for patients with limited treatment options. Amgen is also conducting further trials to explore the potential use of Imdelltra as a first-line treatment option.